These shares are having a stronger day than most. But why? The post Why Orthocell, Paladin Energy, Telix, and Woodside shares ...

Illuccix has gained significant market share due to changes in clinical practice and successful distribution. The company requires minimal capital and is expected to generate very high returns as it ...

Telix Pharmaceuticals Ltd (ASX: TLX) shares are on the move after the ASX 200 biotech stock released its first quarter ...

Telix Pharmaceuticals has reaffirmed its full-year revenue guidance after posting strong first-quarter growth generated from ...

Telix Pharmaceuticals' quarterly report shows a strong revenue contribution from its acquired nuclear medicine business RLS Radiopharmacies.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today provides an update on its commercial and ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

Cardinal Health (NYSE:CAH) has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development ...

TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S ...